Longeveron (NASDAQ:LGVN – Get Free Report) and BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Longeveron and BridgeBio Pharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
| BridgeBio Pharma | 1 | 2 | 19 | 0 | 2.82 |
Longeveron currently has a consensus target price of $80.00, indicating a potential upside of 3,138.87%. BridgeBio Pharma has a consensus target price of $104.42, indicating a potential upside of 33.26%. Given Longeveron’s higher possible upside, equities research analysts plainly believe Longeveron is more favorable than BridgeBio Pharma.
Valuation and Earnings
This table compares Longeveron and BridgeBio Pharma”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Longeveron | $1.20 million | 6.57 | -$22.70 million | ($9.90) | -0.25 |
| BridgeBio Pharma | $502.08 million | 30.40 | -$724.93 million | ($3.04) | -25.78 |
Longeveron has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Longeveron and BridgeBio Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
| BridgeBio Pharma | -59.84% | N/A | -39.81% |
Risk and Volatility
Longeveron has a beta of -0.09, meaning that its share price is 109% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
Institutional and Insider Ownership
10.0% of Longeveron shares are owned by institutional investors. Comparatively, 99.8% of BridgeBio Pharma shares are owned by institutional investors. 7.4% of Longeveron shares are owned by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
BridgeBio Pharma beats Longeveron on 11 of the 14 factors compared between the two stocks.
About Longeveron
Longeveron Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes. Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.
About BridgeBio Pharma
BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions.
Receive News & Ratings for Longeveron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longeveron and related companies with MarketBeat.com's FREE daily email newsletter.
